Abstract: The presently disclosed subject matter relates generally to a treatment garment for use in clothed radiation treatment and diagnosis procedures, and methods of using the garment.

Abstract: Provided herein are compositions and methods for reducing expression of C9orf72 transcripts in cells containing expanded intronic GGGGCC regions, including those in subjects having or at risk of developing amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).

Abstract: Described are compounds and methods useful for the treatment and investigation of Friedreich's Ataxia.

Abstract: Systems, devices, and techniques are described for analyzing evoked compound action potentials (ECAP) signals to assess the effect of a delivered electrical stimulation signal. In one example, a system includes a stimulation generator configured to deliver a stimulation pulse to a patient, sensing circuitry configured to sense an evoked compound action potential (ECAP) signal evoked from the stimulation pulse, and processing circuitry. The processing circuitry may be configured to determine a maximum value of a derivative of the ECAP signal, determine a minimum value of the derivative of the ECAP signal, determine, based on the maximum value of the derivative and the minimum value of the derivative, a characteristic value of the ECAP signal, and determine, based on the characteristic value of the ECAP signal, at least one parameter value at least partially defining electrical stimulation therapy to be delivered to the patient.

Abstract: Provided herein are compositions and methods for reducing expression of C9orf72 transcripts in cells containing expanded intronic GGGGCC regions, including those in subjects having or at risk of developing amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).

Abstract: Described are compounds and methods useful for the treatment and investigation of Friedreich's Ataxia.

Abstract: Systems and methods for authenticating a peripheral device prior to allowing the peripheral device access to components and data stored on user equipment. In some examples, the user equipment may include an authorization component that is configured to physically decouple a hardware interface from other components of the user equipment until the authorization component is able to authenticate the peripheral device. Both authorized peripheral devices and the user equipment may be provisioned with authorization data and/or credentials from a system outside the control of the individual users of the user equipment.

Abstract: Disclosed herein are compounds and methods for modulating C9orf72 transcript. Such compounds and methods are useful to treat, prevent, or ameliorate neurodegenerative diseases in an individual in need thereof.

Abstract: Certain embodiments are directed to methods and compounds for increasing FXN. Such methods and compounds are useful for increasing expression of FXN in cells and animals.

Abstract: Systems and methods for encrypting and decrypting data sent to and received from a peripheral device physically coupled to a hardware interface of a user equipment. In some examples, the user equipment may include an encrypting/decryption component that is configured to physically between a hardware interface of the user equipment and the other components of the user equipment. The encrypting/decryption component may be configured to receive a plurality of encryption/decryption schemes from a remote system. The encrypting/decryption component may select and apply one or more of the plurality of encryption/decryption schemes to data being downloaded and/or uploaded to the peripheral device.

Abstract: Described herein are techniques for performing a trusted execution environment (TEE) detection of systemic malware in a computing system that hosts the TEE. As described, the techniques may include a TEE obtaining data from one or more subsystems of a computing system that hosts the TEE. The TEE is configured to execute components in isolation from the one or more subsystems of the computing system. Based on the data obtained, the TEE detects systemic malware on the one or more subsystems of the computing system. In response to the detected malware, the TEE reports the detection of malware on the one or more subsystems of the computing system.

Abstract: Systems and methods for authenticating a peripheral device prior to allowing the peripheral device access to components and data stored on user equipment. In some examples, the user equipment may include an authorization component that is configured to physically decouple a hardware interface from other components of the user equipment until the authorization component is able to authenticate the peripheral device. Both authorized peripheral devices and the user equipment may be provisioned with authorization data and/or credentials from a system outside the control of the individual users of the user equipment.

Abstract: Provided herein are compositions and methods for reducing expression of C9orf72 transcripts in cells containing expanded intronic GGGGCC regions, including those in subjects having or at risk of developing amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).

Abstract: Disclosed herein are compounds and methods for modulating C9orf72 transcript. Such compounds and methods are useful to treat, prevent, or ameliorate neurodegenerative diseases in an individual in need thereof.

Abstract: Described are compounds and methods useful for the treatment and investigation of Friedreich's Ataxia.

Abstract: Technologies for using edge devices in a cellular network as compute nodes to participate in a blockchain network are described. A cellular network may provision one or more edge devices in communication with the cellular network to instantiate a virtual machine on the edge device to act as a compute node. The cellular network may submit a bid to solve a blockchain hash function using the compute nodes and may instruct the edge to solve the blockchain hash function.

Abstract: Certain embodiments are directed to methods and compounds for increasing FXN. Such methods and compounds are useful for increasing expression of FXN in cells and animals.

Abstract: In a wireless communication network such as a cellular network, cellular devices may receive over-the-air (OTA) configuration commands that specify requested device configuration settings. For example, an OTA configuration command may be a binary short message service (SMS) message specifying a configuration parameter and a requested value of the configuration parameter. Upon receiving an OTA configuration command, the cellular device refers to a blockchain that specifies permissible values for various configuration parameters. If a requested configuration parameter value is not indicated by the blockchain to be permissible, the cellular device disregards the OTA configuration command and refuses to implement the requested setting. The cellular device may periodically retrieve updates to the blockchain and may attempt to validate any updated blocks, based on previously validated blocks. If the updates cannot be validated, the cellular device may decline to implement any requested configuration settings.

Abstract: A temporal identity vault used to authenticate an individual is described herein. User identifying input is received on a device, such as a cell phone. The identifying input is, in some examples, encrypted and stored as a temporal identity vault. The temporal identity vault is configured for a use. The use may be a time, location, or the like. A beacon is associated with the temporal identity vault. If the beacon is at a location relative to an object, the authentication process is started. The information stored in the temporal identity vault is authenticated at a central service. Upon authentication, the user is permitted to operate an object. The temporal identity vault may thereafter be deleted.

Abstract: Provided herein are compositions and methods for reducing expression of C9orf72 transcripts in cells containing expanded intronic GGGGCC regions, including those in subjects having or at risk of developing amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).